tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Entero Therapeutics Amends Rescission Agreement with ImmunogenX

Story Highlights
Entero Therapeutics Amends Rescission Agreement with ImmunogenX

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Entero Therapeutics ( (ENTO) ) just unveiled an announcement.

On July 15, 2025, Entero Therapeutics, ImmunogenX, LLC, and former shareholders of ImmunogenX, Inc. amended their Rescission Agreement to include additional shareholder representations and warranties, such as accredited investor representation. This amendment follows the initial Rescission Agreement intended to unwind a merger agreement dated March 13, 2024, reflecting Entero Therapeutics’ strategic adjustments in its merger activities.

More about Entero Therapeutics

Entero Therapeutics operates in the biotechnology industry, focusing on therapeutic solutions. The company engages in mergers and acquisitions to expand its market presence and enhance its product offerings.

Average Trading Volume: 1,681,697

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.3M

For an in-depth examination of ENTO stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1